drugset

drugset / Trial / NCT01254838

Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma

NCT01254838 ↗

Phase 1 Completed Iwate Medical University Human Genome Center, Institute of Medical Science, University of Tokyo · collab

Summary

The purpose of this study is to evaluate the safety and CTL reaction of novel peptide vaccination for advanced renal cell carcinoma

Timeline

Start: 2008-11
Primary completion: 2010-12
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HIG2	Unknown	—	—

Indications